Drugs / NMS-01940153E
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05630937 | Nov 2020 → Jan 2024 | hepatocellular carcinoma | Nerviano Medical Sciences | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-03-16 | Nerviano Medical Sciences | Results Nerviano Medical Sciences S.r.l. Announces Discontinuation of the Clinical Trial to Evaluate NMS-153 in combination with checkpoint inhibitor/cancer immunotherapy due to Lack of Efficacy in Immune Treatment Experienced Patients. nervianoms.com ↗
The trial confirmed favorable safety profile, but no favorable overall benefit-risk profile. |
| 2023-01-10 | Nerviano Medical Sciences | Results MPS1 (NMS-01940153E) Kinase Inhibitor Shows Clinical Activity in Primary Liver Cancer nervianoms.com ↗
The targeted drug NMS-01940153E, a monopolar spindle 1 (MPS1) kinase inhibitor, has shown signs of clinical activity in a Phase I study of patients with relapsed or refractory unresectable hepatocellular carcinoma (HCC). |
| 2022-10-28 | Nerviano Medical Sciences | Results Nerviano Medical Sciences S.r.l. Shared Data on NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics nervianoms.com ↗
Nerviano Medical Sciences S.r.l. Shared Data on NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics |
| 2022-05-13 | Nerviano Medical Sciences | Results European Journal of Cancer this month published an article on the FIH study in patients with solid tumors conducted with the MPS1 compound NMS-01940153E discovered at NMS S.r.l. nervianoms.com ↗
Based on the positive findings of this first study, NMS is currently developing NMS-01940153E in a phase I/II clinical trial in the setting of hepatocellular carcinoma (HCC). |
All press releases naming this drug 6 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NMS-01940153E | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05630937 ↗ |
| Route | Intravenous | “Route of administration: intravenous (IV) solution” NCT05630937 ↗ |